Immunoassay chip gets new life science seed fund’s first $250K investment
Summary
A chip-based biomarker discovery platform that allows scientists to quickly and simultaneously explore the regulation of several protein targets has garnered $250,000 from a new life science fund. The technology is highly sensitive and allows researchers to run hundreds of tests on a single chip, the company says on its website. Potential applications for the technology include disease biomarkers, drug and vaccine development, allergy testing, infectious disease research, agriculture and food safety. It’s also likely part of $960,000 round of financing the company recently closed, with contributions from non-profit group BioGenerator, St. Louis Arch Angels and other private investors. As a result of those investments, the company, which was founded in New York in 2008, relocated its primary product development and manufacturing activities to St. Louis CEO Rand Henk told the St. Louis Business Journal that the company would aim for a $4 million Series A round this spring.